|
1
|
Kizaka-Kondoh S, Inoue M, Harada H and
Hiraoka M: Tumor hypoxia: a target for selective cancer therapy.
Cancer Sci. 94:1021–1028. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Stewart GD, Ross JA, McLaren DB, Parker
CC, Habib FK and Riddick AC: The relevance of a hypoxic tumour
microenvironment in prostate cancer. BJU Int. 105:8–13. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Movsas B, Chapman JD, Horwitz EM, et al:
Hypoxic regions exist in human prostate carcinoma. Urology.
53:11–18. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Thalmann GN, Anezinis PE, Chang SM, et al:
Androgen-independent cancer progression and bone metastasis in the
LNCaP model of human prostate cancer. Cancer Res. 54:2577–2581.
1994.PubMed/NCBI
|
|
5
|
Culig Z, Hoffmann J, Erdel M, et al:
Switch from antagonist to agonist of the androgen receptor
bicalutamide is associated with prostate tumour progression in a
new model system. Br J Cancer. 81:242–251. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Onishi T, Yamakawa K, Franco OE, et al:
Mitogen-activated protein kinase pathway is involved in alpha6
integrin gene expression in androgen-independent prostate cancer
cells: role of proximal Sp1 consensus sequence. Biochim Biophys
Acta. 1538:218–227. 2001. View Article : Google Scholar
|
|
7
|
Hobisch A, Ramoner R, Fuchs D, et al:
Prostate cancer cells (LNCaP) generated after long-term interleukin
6 (IL-6) treatment express IL-6 and acquire an IL-6 partially
resistant phenotype. Clin Cancer Res. 7:2941–2948. 2001.
|
|
8
|
Kawada M, Inoue H, Usami I, et al:
Establishment of a highly tumorigenic LNCaP cell line having
inflammatory cytokine resistance. Cancer Lett. 242:46–52. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Butterworth KT, McCarthy HO, Devlin A, et
al: Hypoxia selects for androgen independent LNCaP cells with a
more malignant geno- and phenotype. Int J Cancer. 123:760–768.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Iguchi K, Ishii K, Nakano T, et al:
Isolation and characterization of LNCaP sublines differing in
hormone sensitivity. J Androl. 28:670–678. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Iguchi K, Usui S, Ishida R and Hirano K:
Imidazole-induced cell death, associated with intracellular
acidification, caspase-3 activation, DFF-45 cleavage, but not
oligonucleosomal DNA fragmentation. Apoptosis. 7:519–525. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Otsuka T, Iguchi K, Fukami K, et al:
Androgen receptor W741C and T877A mutations in AIDL cells, an
androgen-independent subline of prostate cancer LNCaP cells. Tumour
Biol. 32:1097–1102. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ishii K, Imamura T, Iguchi K, et al:
Evidence that androgen-independent stromal growth factor signals
promote androgen-insensitive prostate cancer cell growth in vivo.
Endocr Relat Cancer. 16:415–428. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Park HJ, Lyons JC, Ohtsubo T and Song CW:
Acidic environment causes apoptosis by increasing caspase activity.
Br J Cancer. 80:1892–1897. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Williams AC, Collard TJ and Paraskeva C:
An acidic environment leads to p53 dependent induction of apoptosis
in human adenoma and carcinoma cell lines: implications for clonal
selection during colorectal carcinogenesis. Oncogene. 18:3199–3204.
1999. View Article : Google Scholar
|
|
16
|
Chang GC, Yu CT, Tsai CH, et al: An
epidermal growth factor inhibitor, gefitinib, induces apoptosis
through a p53-dependent upregulation of pro-apoptotic molecules and
downregulation of anti-apoptotic molecules in human lung
adenocarcinoma A549 cells. Eur J Pharmacol. 600:37–44. 2008.
View Article : Google Scholar
|
|
17
|
Kanai M, Ishii K, Kanda H, et al:
Improvement in predicting tumorigenic phenotype of
androgen-insensitive human LNCaP prostatic cancer cell subline in
recombination with rat urogenital sinus mesenchyme. Cancer Sci.
99:2435–2443. 2008. View Article : Google Scholar
|
|
18
|
Bialik S and Kimchi A: The
death-associated protein kinases: structure, function, and beyond.
Annu Rev Biochem. 75:189–210. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lee TH, Chen CH, Suizu F, et al:
Death-associated protein kinase 1 phosphorylates Pin1 and inhibits
its prolyl isomerase activity and cellular function. Mol Cell.
42:147–159. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Raveh T and Kimchi A: DAP kinase-a
proapoptotic gene that functions as a tumor suppressor. Exp Cell
Res. 264:185–192. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kajiwara T, Takeuchi T, Ueki T, et al:
Effect of Bcl-2 overexpression in human prostate cancer cells in
vitro and in vivo. Int J Urol. 6:520–525. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Shen J, Liu J, Long Y, et al: Knockdown of
survivin expression by siRNAs enhances chemosensitivity of prostate
cancer cells and attenuates its tumorigenicity. Acta Biochim
Biophys Sin. 41:223–230. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Baldi E, Bonaccorsi L and Forti G:
Androgen receptor: good guy or bad guy in prostate cancer invasion?
Endocrinology. 144:1653–1655. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mimeault M and Batra SK: Novel therapies
against aggressive and recurrent epithelial cancers by molecular
targeting tumor- and metastasis-initiating cells and their
progenies. Anticancer Agents Med Chem. 10:137–151. 2010. View Article : Google Scholar
|
